STOCK TITAN
  1. Home
  2. News
  3. VKTX

Viking Therapeutics Inc - VKTX STOCK NEWS

IMPACT
SENTIMENT
VKTX : Nasdaq
Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023
conferences earnings
IMPACT
SENTIMENT
VKTX : Nasdaq
Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
clinical trial
IMPACT
SENTIMENT
VKTX : Nasdaq
Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
clinical trial
IMPACT
SENTIMENT
VKTX : Nasdaq
Viking Therapeutics to Participate at Upcoming Investor Conferences
conferences
IMPACT
SENTIMENT
VKTX : Nasdaq
Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
clinical trial
IMPACT
SENTIMENT
VKTX : Nasdaq VKTX : Nasdaq
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
earnings
IMPACT
SENTIMENT
VKTX : Nasdaq VKTX : Nasdaq
Viking Therapeutics to Report Financial Results for Second Quarter 2023 on July 26, 2023
conferences earnings
IMPACT
SENTIMENT
LGND : Nasdaq VKTX : Nasdaq
Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
clinical trial
IMPACT
SENTIMENT
VKTX : Nasdaq VKTX : Nasdaq
Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
clinical trial
IMPACT
SENTIMENT
VKTX : Nasdaq
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
earnings
Stock VKTX logo
Viking Therapeutics Inc
Nasdaq:VKTX

VKTX Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About VKTX

novel therapeutics for metabolic and endocrine disorders.